CHOKSI ASIA LIMITED is a Healthcare Equipment & Supplies company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 2 | 1 | 1 | 37 | 49 |
| EBITDA (ex other income) | (2) | (1) | (2) | 4 | 7 |
| margin % | (94.1) | (187.3) | (145.9) | 10.3 | 13.8 |
| Owners' profit | (0) | (0) | (0) | 3 | 5 |
| EPS, as reported (₹) | (1.08) | (1.22) | (1.17) | 5.44 | 9.36 |
| ROE % · ROCE % | (2.6) · (2.8) | (3.1) · (2.7) | (3.0) · (6.2) | 8.4 · 12.8 | 12.7 · 18.4 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.13 | 0.05 |
| Cash from operations | (1) | (3) | 1 | (3) | 1 |
| Capex | (0) | (0) | (0) | (1) | (1) |
| ₹ crore | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 1 | 6 | 9 | 12 | 12 | 13 | 12 | 12 |
| Profit before tax | 0 | 0 | 0 | 1 | 2 | 2 | 2 | 2 |
| Net profit | 0 | 0 | 0 | 1 | 1 | 1 | 2 | 1 |
| EPS (₹) | 0.92 | 0.62 | 0.36 | 1.24 | 1.88 | 2.36 | 3.73 | 1.32 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| POLY MEDICURE LIMITED | 17,626 | 55.9 | 5.60 | 32.3 | 10.2 | 12.6 | 19.0 | 30.2 |
| FISCHER MEDICAL VENTURE L | 2,353 | 15.0 | 6.11 | 43.6 | 8.1 | 11.3 | — | 15.5 |
| TARSONS PRODUCTS LIMITED | 1,657 | 149.0 | 2.61 | 14.3 | 2.3 | 2.4 | — | 29.0 |
| LAXMI DENTAL LIMITED | 1,121 | 36.0 | 4.59 | 24.1 | 11.8 | 11.0 | — | 22.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 8 Sept 2026 · Newspaper notice published for 34th AGM and e-voting | compliance | minimal | — | — |
| 7 Sept 2026 · Choksi Asia files 34th Annual Report for FY2025-26, AGM on Sep 29 | board shareholder meetings | medium | — | — |
| 6 Sept 2026 · Notice published for 34th Annual General Meeting | compliance | minimal | — | — |
| 4 Sept 2026 · Intimation of 34th Annual General Meeting on September 29, 2026 | board shareholder meetings | low | — | — |
| 12 Aug 2026 · Newspaper publication of Q1 FY26 unaudited financial results | compliance | minimal | — | — |
| 11 Aug 2026 · Q1 FY26 revenue falls 22.5% YoY; PAT slips to Rs 96.17 lakh | results | high | — | — |
| 11 Aug 2026 · Choksi Asia Q1 FY27: Revenue down 22%, PAT down 10% YoY | results | high | — | — |
| 4 Aug 2026 · BSE seeks clarification on price movement from Choksi Asia | regulatory legal | high | — | — |
| 9 Jul 2026 · Routine compliance certificate for share dematerialisation filed with BSE | compliance | minimal | — | — |
| 7 Jul 2026 · Registered office shifted from Maharashtra to Dadra and Nagar Haveli | general | low | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| FABTECH TECHNOLOGIES LTD |
| 650 |
| 10.6 |
| 1.55 |
| 10.6 |
| 9.1 |
| 10.7 |
| — |
| 9.9 |
| Hemant Surgical Industries Lim | 613 | 23.4 | — | — | — | 16.7 | — | — |
| Prevest Denpro Limited | 489 | 16.5 | — | — | — | 21.9 | — | — |
| NURECA LIMITED | 318 | 65.2 | 1.76 | 38.3 | 1.2 | 2.7 | (7.2) | 13.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 23.1 | 20.0 | 10 of 17 | 44% |
| P/B | 2.9 | 2.7 | 8 of 11 | 30% |
| ROCE | 17.4 | 11.3 | 4 of 17 | 81% |
| ROE | 12.7 | 8.1 | 2 of 11 | 90% |
| Debt / Equity | 0.1 | 0.1 | 4 of 11 | 70% |
| EBITDA margin | 19.5 | 16.7 | 5 of 11 | 60% |
| Revenue growth | (2.4) | 13.9 | 11 of 13 | 17% |
| Profit growth | 6.2 | 75.5 | 7 of 10 | 33% |
| Market cap | 122 | 175 | 10 of 17 | 44% |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
